Business Context and Reporting Period
This Form 8-K is filed by OncoCyte Corporation (trading symbol: OCX) on May 7, 2020. The report primarily addresses executive compensation deferrals and incorporates by reference the press release regarding financial results for the three months ended March 31, 2020, which was issued on May 12, 2020.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the text of this 8-K.
Material Changes and Executive Compensation
On May 7, 2020, OncoCyte entered into Deferral Agreements with its executive officers and non-employee directors to defer portions of their compensation through December 4, 2020. Key terms include:
- CEO Ronald Andrews: Deferred 30% of base salary and $186,240 of a discretionary bonus. Additionally, he accepted 106,221 Restricted Stock Units (RSUs) valued at $279,360 (based on a $2.63 share price) in lieu of cash bonus. Deferred amounts bear interest at 10% (salary) and 6% (bonus).
- CFO Mitchell Levine and CSO Lyndal Hesterberg: Each deferred 20% of base salary, bearing interest at 6% per annum.
- Settlement Terms: Deferral payments will be settled by December 31, 2020, or upon termination/change in control. Settlement may be cash, stock, or a combination, with a minimum of 40% paid in cash.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially from anticipated results due to risk factors detailed in the company's Form 10-K and Form 10-Q. No specific operational guidance or new risk factors are introduced in this document.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 12, 2020) for specific Q1 2020 financial results (revenue, net loss, cash position).
- Verify the total cash impact of the executive deferrals versus the equity grant of 106,221 RSUs to the CEO.
- Confirm the company's current cash runway and liquidity status as reported in the Q1 2020 results.
- Monitor the vesting schedule of the CEO's RSUs (vesting May 7, 2021) and potential dilution effects.